Introduction
Two thousand three hundred people die annually in the United Kingdom from renal cell carcinoma' and the median survival for patients with metastatic disease is nine months. In the last decade, major developments in molecular biology and immunology have led to a spectacular improvement in the prognosis for a proportion of patients with this malignancy. In this article we review treatment options for metastatic renal cancer.
Hormonal therapy
In the 1 970s there seemed to be real reason to hope that hormonal therapies might be effective for renal cell carcinoma and these hopes came from empirical observations ofthe effects of treatment in animals. Renal cell cancer in the Syrian golden haired hamster was shown to regress following orchiectomy and from this model hormonal therapies developed.
Steroid hormone receptors
Renal cell carcinoma contains receptors for steroid hormones and these include dihydrotestosterone, 17 beta oestradiol and progesterone. In one series 11 of 55 renal cancers were oestrogen receptor positive, 4 of 55 progesterone receptor positive and 10 of 53 testosterone receptor positive.2 In a second series, twelve of 62 tumours assayed for steroid hormone binding were found to coniain dihydrotestosterone receptors.3 In another series of 41 renal carcinomas, 30 were androgen receptor positive, 11 oestrogen receptor positive and 11 progesterone receptor positive. In this series survival directly correlated with receptor positivity and those patients whose tumours expressed more than one receptor survived for longer than those who were receptor negative. 4 In another series 16 of 19 patients' tumours were testosterone receptorpositive, one of 19 oestrogen receptor-positive and 20 were dihydrotestosterone receptor-positive. In these patients the level of dihydrotestosterone positivity directly correlated with clinical stage and the more advanced tumours had higher levels. Receptor status was examined in the normal kidney and a virtual concordance of positivity was found when tumour was compared with normal tissue.5
Hormonal treatment
A number of different hormonal therapies have been applied to the management of patients with metastatic renal cell cancer. Their attractiveness as a therapy for malignant disease lies in their comparative lack of toxicity as compared to cytotoxic chemotherapy or biological agents. Amongst the first to be used was medroxyprogesterone acetate and in an initial report a response rate of 27% was described by Julian Bloom.6 Because of this encouraging finding medroxyprogesterone acetate has been applied in different dosages and schedules to large numbers ofpatients. At a dosage of 500 mg given intramuscularly daily for 6 weeks and thereafter twice weekly, three of 20 patients were seen to have responded. In this study tumour ploidy was assessed and it was found that those patients who responded had diploid tumours.7 In a group of 18 patients with advanced disease, medroxyprogesterone acetate was given at a dosage of 800 mg intramuscularly weekly and no responses were seen.8 Twenty one patients were treated with 500-1000 mg daily intramuscularly and one partial response was seen.9 Megesterol acetate was responsiveness. However, there are additional effects that are important and these relate to the anabolic qualities of this group of compounds which lead to increased weight and appetite which are welcomed by patients.
Flutamide is a pure antiandrogen without central affects which competitively binds to the androgen receptor. Twenty eight patients were treated with a dosage of 250 mg of flutamide thrice daily orally; 25 patients were assessable and one had a partial response. 2 Because of the finding of oestrogen receptors within renal cell carcinomas tamoxifen has been used and at a dose of 20 mg twice daily, responses were reported in 8 of 79 patients."
Cytotoxic chemotherapy
Among agents considered to be effective in the treatment of renal cell carcinoma, vinblastine and CCNU are the most active. However, the order of response is low at less than 10%.12 In order to improve upon the results obtained, these agents have been applied in unconventional schedules and in combination. CCNU at a dosage of 120 mg/M2 was given on day one and vinblastine at a dosage of 0.1 mg/kg on days 1 and 8 of a 6-week treatment cycle. No responses were seen in 15 patients.'3 Vinblastine was given as an infusion at a dosage of 1.5 mg/M2 daily for 5 days, three weekly to 14 patients one of whom responded.'4 Methotrexate given in combination with vinblastine and bleomycin with or without tamoxifen resulted in 10 partial responses ofmedian duration 57 weeks in 34 treated patients.'5 Vinblastine at a dosage of 5 mg/ m2 on day one, CCNU at 60 mg/M2 on day 2 and hydroxyurea at 400 mg/M2 twice daily on days 3 and 14 of a 4-week treatment cycle together with medroxyprogesterone acetate I g intramuscularly weekly led to three partial responses in 26 patients. 16 Other newer agents have been applied to the treatment of renal cell carcinoma with almost as little effect as more established therapies. Mitozantrone is an anthracycline with less cardiotoxicity than adriamycin, which does not result in significant nausea nor alopecia. Fifty eight patients with advanced renal cell carcinoma were treated with this agent at a dosage of 5 mg/M2 weekly; no responses were seen.'7 4-Demethoxydaunorubicin, an adriamycin derivative without significant cardiac toxicity, was given at a dosage of 12.5 mg/m2 three weekly to 19 patients, none of whom responded. ' In vitro studies have demonstrated a greater antitumour effect of interferon gamma as compared to beta or alpha interferon. The activity of gamma interferon was investigated by Garnick et al. in a Phase 1/2 study; 41 patients were treated with either a daily 2 hour infusion or a 24 hour infusion ofgamma interferon given for 7 days every 3 weeks; the dosage was increased from 10 mg/m2 to 3,000 mg/m2. Dose limiting toxicity occurred between 1,000 and 3,000 mg/m2 with one complete response and three partial responses. 25 Interferons do have side effects, the most common ofwhich are flu-like symptoms occurring approximately one hour after injection and lasting from 2 to 3 hours. These may be eased by simple agents such as aspirin given an hour prior to interferon administration. More significant side effects such as alopecia, marrow suppression and changes in hepatic and renal function are reported at all dosages and schedules of interferon administration.
Interferons and chemotherapy
The synergistic effects of interferon given with cytotoxic chemotherapy have been investigated; 24 patients were treated with vinblastine at a dosage of 0.15 mg per kilogram weekly and buffy coated interferon at a dosage of 3 megaunits, 5 times weekly and led to 3 partial responses. 26 Interferon alpha 2a at a dosage of 10 megaunits intramuscularly with vinblastine 0.075 mg/kg, 3-weekly given to 20 patients or 0.1 mg/kg of vinblastine 3- weekly was given to 18 patients and resulted in one complete and 16 partial responses. 27 It would seem then that there is no synergistic effect between vinblastine and interferon and that the effects ofthe interferons are not exactly optimal in the management of this disease. The true complete response rate seems to be approximately 10% for a median duration of between 4 and 6 months.
Adoptive immunotherapy
Much of the original work in this field was pioneered by Rosenberg at the National Cancer Institute, Bethesda, Maryland. His initial studies were carried out in animals where he demonstrated that interleukin-2 alone or in combination with lymphokine-activated killer cells decreased the size of pulmonary and hepatic metastases from experimental tumours.28 In 1983 clinical trials began in patients with advanced disseminated cancer in whom conventional therapy had failed, and encouragingly high response rates were reported in solid tumours, unresponsive to conventional therapies. 29, 30 1. Interleukin-2: mechanisms ofaction IL-2 is a chemically defined lymphokine, originally described as a T-cell growth factor causing proliferation of activated T-cells. It Any current attempt to explain the interactions of IL-2, effector cells and other cytokines is simplistic because a number of interacting and complex mechanisms seem to be involved. Furthermore, it may be that different processes are involved in the mechanisms of tumour cytotoxicity in different malignancies and in different organs involved with metastatic disease from the same primary cancer. The effect of IL-2 may be a humoral one as a result of cytokine activity, a cellular cytotoxic effect involving predominantly T-cells or an indirect effect on vascular endothelium resulting in ischaemic tumour necrosis.
Interleukin 2: dosage schedules
The attainment of the 'correct' dosage regimens and routes ofadministration of IL-2 in humans has been expedited by animal work. Initially, IL-2 was used in high dosages, as repeated bolus injections, alone or with LAK-cells. After an intravenous bolus IL-2 has a distribution half-life of 7 to 10 minutes and a clearance half-life of 30 to 60 minutes. The establishment of correct dosage schedules has been virtually serendipitous where side effects have been titrated against clinical responses. Recently a number of studies have been carried out involving low dose recombinant IL-2 and the results have been encouraging. It would appear that achieving toxicity with IL-2 therapy is not a prerequisite for response.3 '32 In an attempt to produce regimens with less toxicity rIL-2 has been given as a continuous infusion. 33 Increased experience of biological response modifiers led to the view that 'area under the curve' was important but not the maximum tolerated dose, unlike conventional chemotherapy. 
Conclusion
The prospect for the patient with renal cell cancer has definitely improved as a result of the treatment group.bmj.com on September 30, 2017 -Published by http://pmj.bmj.com/ Downloaded from advances of the last five years. In a significant proportion of patients, metastatic disease can be cured and a better future is promised as cytokine treatment is further refined.
